MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.831 MCO-0-0-831 Articles Association between preoperative serum total cholesterol level and biochemical recurrence in prostate cancer patients who underwent radical prostatectomy OHNOYOSHIO OHORIMAKOTO NAKASHIMAJUN OKUBOHIDENORI SATAKENAOYA HASHIMOTOTAKESHI TACHIBANAMASAAKI Department of Urology, Tokyo Medical University, Tokyo 1600023, Japan Correspondence to: Dr Yoshio Ohno, Department of Urology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 1600023, Japan, E-mail: yoshio-o@tokyo-med.ac.jp 06 2016 28 03 2016 4 6 1073 1077 04092015 07032016 Copyright © 2016, Spandidos Publications 2016

The aim of this study was to investigate the association between serum total cholesterol (TC) level and biochemical recurrence (BCR) following radical prostatectomy (RP). The study included 562 patients with T1-3N0M0 prostate cancer, who underwent RP at our institution between 2002 and 2010. No patients received neoadjuvant and/or adjuvant therapy. The associations between preoperative TC level, clinicopathological factors and BCR were assessed using univariate and multivariate analyses. During follow-up (mean, 54.0 months), 168 patients (168/562, 29.9%) experienced BCR, with a 5-year BCR-free rate of 67.2%. Of the clinicopathological characteristics investigated, statin use and lymphovascular invasion (LVI) status were associated with lower TC level (P=0.003 and P=0.014, respectively). In the univariate analysis, a higher serum prostate-specific antigen (PSA) level at diagnosis, extracapsular extension, positive surgical margin, seminal vesicle invasion, LVI, perineural invasion, higher Gleason score (GS ≥8) based on the RP specimen, increased body mass index, and low preoperative TC level, were significantly associated with BCR. In the multivariate analysis, the TC level was an independent predictor of BCR (hazard ratio = 0.925 per 10 mg/dl; 95% confidence interval: 0.879–0.973; P=0.003), as was the serum PSA level, extracapsular extension, positive surgical margin and the GS. Low preoperative serum TC levels were associated with an increased risk of BCR among prostate cancer patients who underwent RP. Our findings suggest that the preoperative serum TC level may provide important clinical information that may prove to be useful in patient counseling.

 prostate cancer prostatectomy total cholesterol recurrence prostate-specific antigen Introduction

Following introduction of the prostate-specific antigen (PSA) screening test, the majority of prostate cancer patients are diagnosed in the early stages of the disease and undergo definitive local treatment, such as radical prostatectomy (RP) and radiotherapy. However, a subset of patients experience biochemical recurrence (BCR) or succumb to prostate cancer (1,2). Thus, prevention of recurrence and progression to lethal prostate cancer represents a major public health challenge.

The established risk factors for prostate cancer are age, race and family history, which are all non-modifiable (1). To date, several researchers have investigated the association between modifiable lifestyle factors, such as obesity, smoking and a high-fat diet, and the risk and prognosis of prostate cancer (1,3). The identification of modifiable factors that affect the clinical course of prostate cancer may be useful for preventing recurrence and progression after definitive local treatment. Recent studies have demonstrated a decreased risk of high-grade prostate cancer in men with lower circulating total cholesterol (TC) levels (4–6). In addition, several studies reported that statin, a cholesterol-lowering drug, may protect against high-stage or high-grade prostate cancer (7). Furthermore, it has been demonstrated that statins decrease the risk of BCR or prostate cancer-specific mortality (8,9). However, to date, only a limited number of studies have investigated the association between pretreatment serum TC level and the prognosis of prostate cancer, particularly in the PSA era. The aim of this study was to investigate the clinical implications of preoperative serum TC level in Japanese prostate cancer patients who underwent RP.

 Patients and methods <sec> <title>Patients

This retrospective study was conducted according to the ethical guidelines for clinical studies of the Ministry of Health, Labor and Welfare of Japan, and was approved by the ethics committee of our institution (no. 1621). Clinical data from 719 Japanese patients who underwent RP and pelvic lymph node dissection for clinical T1-3N0M0 prostate cancer at our institution from 2000 to 2010 were collected by reviewing the patients' medical charts. Patients who received neoadjuvant hormonal therapy (n=112) or high-intensity focused ultrasonography (n=1) and patients with unavailable serum TC level data (n=44) were excluded from the study. Finally, a total of 562 patients were included in our study. These patients were treated by open retropubic (n=316) or robot-assisted (n=246) RP, and only lymph node sampling was performed. Clinical stages were assigned according to the 2002 TNM staging system (10), and pathology outcomes, such as pathological stage, status of surgical margins, lymphovascular invasion (LVI), perineural invasion (PNI) and the Gleason score (GS) of the RP specimens, were obtained from the official pathology reports. Peripheral blood samples were primarily obtained from all the patients at the time of hospitalization. Data on statin use was extracted from the patients' records at the time of RP. Body mass index (BMI) was calculated as weight (kg) divided by the square of the height (m2) and expressed as kg/m2.

 Data analyses

The data were expressed as mean ± standard deviation (SD). The primary outcome measure in this study was BCR. The time of BCR was defined as the earliest date that the postoperative serum PSA levels increased to ≥0.2 ng/ml, and BCR was confirmed by a second PSA examination result that was equal to or higher than the initially recorded PSA levels. The day of surgery was reported as the PSA recurrence day if postoperative serum PSA levels did not decrease to ≤0.1 ng/ml. Factors analyzed included age at RP, preoperative serum PSA levels, BMI, preoperative serum TC level, statin use, and all relevant pathological factors [GS, extracapsular extension (ECE), seminal vesicle invasion (SVI), surgical margin status, LVI, PNI and lymph node metastasis] of the RP specimen. Age at RP, preoperative serum PSA levels, BMI and preoperative TC level were included as continuous variables. BMI was also analyzed as a categorical variable in the Cox regression analyses. Patients were classified using the World Health Organization criteria as follows: BMI <25 kg/m2 (normal weight), BMI 25–30 kg/m2 (overweight) and BMI ≥30 kg/m2 (obesity) (11). The variables of the different groups were compared using the Pearson's chi-square test, the Mann-Whitney U test, or analysis of variance. Univariate and multivariate Cox regression analyses were performed to assess the association between BCR and the clinicopathological variables. Multivariate Cox regression analyses were performed using a forward stepwise variable selection procedure, and survival curves were constructed using the Kaplan-Meier method with log-rank tests. The patients were divided into two groups by the cut-off identified by the root node in a recursive partitioning analysis according to the previous report by de Martino et al (12). All P-values were two-tailed, and P-values <0.05 were considered to indicate statistically significant differences. All statistical analyses were performed using Stata software, version 11 (StataCorp, College Station, TX, USA) and JMP software, version 9 (SAS Institute, Cary, NC, USA).

 Results <sec> <title>Serum TC level and clinicopathological factors

The patients' characteristics are summarized in Table I. The mean ± SD serum TC level of all patients was 209±32.1 mg/dl (median, 209 mg/dl; interquartile range, 190–230 mg/dl). The serum TC level was found to be significantly correlated with age (Spearman's r = −0.101, P=0.016), but not with PSA level (P=0.737) or BMI (P=0.274) (data not shown). In addition, low TC level was found to be significantly associated with statin use and presence of LVI (P=0.003 and P=0.014, respectively; Table II).

 Serum TC level and prognosis

During follow-up (mean, 54.0 months), 168 patients (168/562, 29.9%) experienced BCR, with a 5-year BCR-free rate of 67.2%. In the univariate analysis, a higher serum PSA level at diagnosis, advanced clinical tumor stage, ECE, positive surgical margin, SVI, LVI, PNI, higher GS (GS ≥8) based on the RP specimen, increased BMI, and a lower preoperative serum TC level, were significantly associated with BCR (Table III). BCR-free survival curves according to the TC level are presented in Fig. 1. The cut-off TC level was defined by recursive partitioning analysis. The 5-year BCR-free rate in patients with high TC level (TC ≥220 mg/dl) was higher compared with that in patients with low TC levels (TC <220 mg/dl) (72.8 vs. 64.0%, respectively; P=0.014).

In the multivariate analysis, the serum TC level was an independent predictor of BCR [hazard ratio (HR) = 0.925 per 10 mg/dl; 95% confidence interval (CI): 0.879–0.973; P=0.003), as was the serum PSA level, ECE, positive surgical margin and GS (Table III).

In subpopulation analyses by statin use or surgical margin status, univariate analyses demonstrated that lower preoperative serum TC level was significantly associated with BCR in the statin non-user group (HR=0.941 per 10 mg/dl; 95% CI: 0.983–0.991; P=0.021) and in the negative surgical margin group (HR=0.883 per 10 mg/dl; 95% CI: 0.799–0.975; P=0.014).

 Discussion

In this study, we demonstrated that low preoperative TC levels were significantly associated with an increased risk of BCR following RP. Previous epidemiological studies demonstrated that lower serum TC level was associated with lower risk of high-grade prostate cancer and advanced disease (4–6). It was also reported that hypercholesterolemia accelerates the growth of prostatic tumors in vivo (13). Therefore, we hypothesized that an elevated preoperative serum TC level may be associated with increased risk of BCR following RP. Contrary to our expectations, there was no significant association between preoperative serum TC level and GS and clinical stage in the present study. A Cox proportional hazard model demonstrated a dose-dependent inverse association between preoperative TC level and the risk of BCR.

To date, only a limited number of studies have described the association between serum TC level and prostate cancer prognosis. Eichholzer et al reported that low plasma TC level (<199 mg/dl) was significantly associated with an increased risk of prostate cancer mortality in individuals aged >60 years (14). Batty et al reported that elevated blood TC level was associated with death from prostate cancer (15). These results are inconsistent. Although it has been reported that a high TC level accelerates proliferation of prostate cancer cells, the serum TC level decreases by effect of cancer metabolism as the disease progresses (16). Thus, it may be important to consider the time interval between serum TC measurement and prostate cancer diagnosis, and the extent of the disease when investigating the association between serum TC level and prostate cancer prognosis. Solomon et al suggested that a relatively low TC level within 1 year of a prostate cancer diagnosis raises the risk of prostate cancer-related death; a relatively low TC level may indicate more advanced disease. On the other hand, a relatively low TC level >6 years prior to prostate cancer diagnosis reduces the risk of prostate cancer-related death; this may be associated with lower risk of high-grade cancer or aggressive disease (16). Although serum TC level in the present study was measured within 3 months after prostate cancer diagnosis, serum TC level in previous epidemiological studies by Platz et al and Mondull et al, which demonstrated that a lower serum TC level was associated with lower risk of high-grade prostate cancer and advanced disease, was measured at least 2 years prior to prostate cancer diagnosis (4–6). Thus, there may have been a significant difference in the clinical implications of the serum TC level in these studies.

The association between a relatively low serum TC level and BCR remains to be elucidated. The present study included only clinically localized disease. Thus, it was unlikely that serum TC levels were affected by prostate cancer cells. One potential explanation for the observed association between serum TC level and BCR is an association between serum TC and immune system function. It has been reported that men with hypocholesterolemia had significantly fewer circulating lymphocytes, fewer total T cells, and fewer CD8+ cells compared with th ose with hypercholesterolemia (17). Thus, patients with relatively high TC levels may have a better antitumor immune status compared with patients with relatively low TC levels.

Although this study highlights the important clinical implications of preoperative serum TC level in prostate cancer patients who underwent RP, it has some limitations. First, this is a retrospective analysis of data collected from a single institution; thus, the number of cases was relatively small. Second, there may be differences in patient characteristics between studies on BCR and prostate cancer in Western countries and those in Asian countries. In Western studies, over half the study population is overweight or obese (BMI ≥25 kg/m2) (18–20), whereas <50% of the study populations in Asian studies have a BMI of ≥25 kg/m2 (21,22). However, serum TC levels appear to be similar in Asian and Western studies (4,5,14,23). Third, we only analyzed the association of the TC level with BCR, since our routine preoperative laboratory examination did not include assessment of LDL and HDL cholesterol levels. We may need to investigate the association between LDL and HDL cholesterol levels and BCR in the future. Despite these limitations, however, this is the first study to demonstrate an inverse association between preoperative serum TC level and BCR following RP. Our findings suggest that the preoperative serum TC level may provide important clinical information that may prove be useful in patient counseling. However, further large cohort studies, including different countries and regions, are warranted to validate the clinical value of preoperative serum TC level in prostate cancer patients.

In conclusion, low preoperative serum TC levels were significantly associated with an increased risk of BCR among prostate cancer patients who underwent RP. However, our findings require validation by future studies.

 Acknowledgements

The present study was partially supported by the MEXT-Supported Program for the Strategic Foundation at Private Universities, 2013–2017.

 References HeidenreichABellmuntJBollaMJoniauSMasonMMatveevVMottetNSchmidHPvan der KwastTWiegelTEAU guidelines on prostate cancer Part 1: Screening, diagnosis, and treatment of clinically localised diseaseEur Urol596171201110.1016/j.eururo.2010.10.03921056534 MottetNBellmuntJBollaMJoniauSMasonMMatveevVSchmidHPvan der KwastTWiegelTZattoniFHeidenreichAEAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol59572583201110.1016/j.eururo.2011.01.02521315502 WilsonKMGiovannucciELMucciLALifestyle and dietary factors in the prevention of lethal prostate cancerAsian J Androl14365374201210.1038/aja.2011.14222504869 PlatzEAClintonSKGiovannucciEAssociation between plasma cholesterol and prostate cancer in the PSA eraInt J Cancer12316931698200810.1002/ijc.2371518646186 PlatzEATillCGoodmanPJParnesHLFiggWDAlbanesDNeuhouserMLKleinEAThompsonIMJrKristalARMen with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialCancer Epidemiol Biomarkers Prev1828072813200910.1158/1055-9965.EPI-09-047219887582 MondulAMClippSLHelzlsouerKJPlatzEAAssociation between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohortCancer Causes Control216168201010.1007/s10552-009-9434-819806465 PlatzEALeitzmannMFVisvanathanKRimmEBStampferMJWillettWCGiovannucciEStatin drugs and risk of advanced prostate cancerJ Natl Cancer Inst9818191825200610.1093/jnci/djj49917179483 AllottEHHowardLECooperbergMRKaneCJAronsonWJTerrisMKAmlingCLFreedlandSJPostoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseBJU Int114661666201410.1111/bju.1272024588774 YuOEbergMBenayounSAprikianABatistGSuissaSAzoulayLUse of statins and the risk of death in patients with prostate cancerJ Clin Oncol32511201410.1200/JCO.2013.49.475724190110 SobinLHWittekindCHUICCTNM Classification of Malignant Tumours6thWileyNew York2002 World Health Organization: Obesity: Preventing and Managing the Global EpidemicWHO Technical Report Series no 894WHO, Geneva2000 de MartinoMLeitnerCVSeemannCHofbauerSLLuccaIHaitelAShariatSFKlatteTPreoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC)BJU Int115397404201510.1111/bju.1276724698164 ZhuangLKimJAdamRMSolomonKRFreemanMRCholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenograftsJ Clin Invest115959968200510.1172/JCI20051993515776112 EichholzerMStähelinHBGutzwillerFLüdinEBernasconiFAssociation of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel studyAm J Clin Nutr71569572200010648273 BattyGDKivimäkiMClarkeRSmithDavey GShipleyMJModifiable risk factors for prostate cancer mortality in London: Forty years of follow-up in the Whitehall studyCancer Causes Control22311318201110.1007/s10552-010-9691-621116843 SolomonKRFreemanMRThe complex interplay between cholesterol and prostate malignancyUrol Clin North Am38243259201110.1016/j.ucl.2011.04.00121798387 MuldoonMFMarslandAFloryJDRabinBSWhitesideTLManuckSBImmune system differences in men with hypo- or hypercholesterolemiaClin Immunol Immunopathol84145149199710.1006/clin.1997.43829245545 AmlingCLKaneCJRiffenburghRHWardJFRobertsJLLanceRSFriedrichsPAMoulJWRelationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomyUrology58723728200110.1016/S0090-4295(01)01373-511711349 SiddiquiSAInmanBASenguptaSSlezakJMBergstralfEJLeibovichBCZinckeHBluteMLObesity and survival after radical prostatectomy: A 10-year prospective cohort studyCancer107521529200610.1002/cncr.2203016773619 LoebSYuXNadlerRBRoehlKAHanMHawkinsSACatalonaWJDoes body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?J Urol177102106discussion 106200710.1016/j.juro.2006.08.09717162013 NaritaSMitsuzukaKYoneyamaTTsuchiyaNKoieTKakoiNKawamuraSKaihoYOyamaCTochigiTImpact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomyProstate Cancer Prostatic Dis16271276201310.1038/pcan.2013.1623752230 LeeSELeeWKJeongMSAbdullajanovMKimDSParkHZJeongSJYoonCYByunSSChoeGIs body mass index associated with pathological outcomes after radical prostatectomy in Korean men?BJU Int10712501255201110.1111/j.1464-410X.2010.09592.x20880194 KitaharaCMde BerringtonGonzález AFreedmanNDHuxleyRMokYJeeSHSametJMTotal cholesterol and cancer risk in a large prospective study in KoreaJ Clin Oncol2915921598201110.1200/JCO.2010.31.520021422422

Biochemical recurrence-free survival rate according to preoperative serum total cholesterol level.

Patient characteristics (n=562).

Characteristics Valuesa
Age, years 65.9±6.4
Psa, ng/ml 10.6±10.1
Body mass index, kg/m2 23.7±2.9
  <25 377 (67.1)
  25–30 170 (30.2)
  ≥30 15 (2.7)
Total serum cholesterol, mg/dl 209±32.1
Statin use
  No 493 (87.7)
  Yes 69 (12.3)
Clinical stage
  T1c 417 (71.2)
  T2 136 (27.2)
  T3 9 (1.6)
Pathological factors
RP Gleason score
  ≤6 100 (17.8)
  7 338 (60.1)
  ≥8 124 (22.1)
Extracapsular extension
  (−) 381 (67.8)
  (+) 181 (32.2)
Seminal vesicle invasion
  (−) 511 (90.9)
  (+) 51 (9.1)
Surgical margin
  (−) 306 (54.4)
  (+) 256 (45.6)
Lymphovascular invasion
  (−) 414 (73.7)
  (+) 148 (26.3)
Perineural invasion
  (−) 242 (43.1)
  (+) 320 (56.9)
Lymph node metastases
  (−) 555 (98.8)
  (+) 7 (1.2)

Presented as mean ± standard deviation or numbers (percentages). RP, radical prostatectomy.

Association between serum TC level and clinicopathological factors.

Serum TC level
Factors Mean SD P-value
Statin use 0.003
  No 211 31.7
  Yes 199 33.0
Clinical T stage 0.292
  T1c 209 32.6
  T2a 217 32.1
  T2b 211 28.2
  T2c 204 8.3
  T3 213 10.7
Gleason score 0.280
  ≤7 211 32.0
  ≥8 207 32.2
Extracapsular extension 0.867
  (−) 210 30.4
  (+) 210 35.5
Seminal vesicle invasion 0.229
  (−) 210 32.2
  (+) 204 30.5
Surgical margin 0.232
  (−) 208 32.0
  (+) 212 32.2
Lymphovascular invasion 0.014
  (−) 211 31.9
  (+) 204 32.1
Perineural invasion 0.663
  (−) 209 32.1
  (+) 210 32.1
lymph node metastases 0.834
  (−) 210 32.2
  (+) 212 22.5

SD, standard deviation; TC, total cholesterol.

Results of univariate and multivariate analyses.

Univariate Multivariate
Variables HR P-value HR 95% CI P-value
Age at diagnosis, years
  Continuous 1.022 0.087 0.896
PSA, ng/ml
  Continuous 1.034 <0.001 1.018 1.007–1.029 0.002
Statin use
  No vs. yes 1.211 0.442 0.120
Clinical T stage
  1 1
  2 1.593 0.006 0.522
  3 10.681 <0.001 0.021
Gleason score
  ≤7 vs. ≥8 2.816 <0.001 1.596 1.107–2.302 0.012
Extracapsular extension
  (−) vs. (+) 3.910 <0.001 1.687 1.136–2.503 0.009
Seminal vesicle invasion
  (−) vs. (+) 4.160 <0.001 0.192
Surgical margin
  (−) vs. (+) 4.191 <0.001 2.564 1.701–3.864 <0.001
Lymphovascular invasion
  (−) vs. (+) 2.279 <0.001 0.184
Perineural invasion
  (−) vs. (+) 1.913 <0.001 0.799
Lymph node metastases
  (−) vs. (+) 4.144 0.002 0.184
Body mass index, kg/m2
  Continuous 1.064 0.018 0.240
Body mass index, kg/m2
  <25 1 – – –
  25–30 1.202 0.266
  ≥30 2.716 0.007
Serum total cholesterol (10 mg/dl)
  Continuous 0.995 0.030 0.925 0.879–0.97 0.003

HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.